Neurodegenerative disease risk among former international rugby union players

Emma R Russell,1 Daniel F Mackay,2 Donald Lyall, Katy Stewart,3,4 John A MacLean,3,4 James Robson,5 Jill P Pell,2 William Stewart 1,6

ABSTRACT

Background Autopsy studies of former contact sports athletes, including soccer and rugby players, frequently report chronic traumatic encephalopathy, a neurodegenerative pathology associated with traumatic brain injury. Nevertheless, little is known about the risk of neurodegenerative disease in these populations. We hypothesised that neurodegenerative disease risk would be higher among former elite rugby union players than the general population.

Methods We conducted a retrospective cohort study accessing national electronic records on death certification, hospital admissions and dispensed prescriptions for a cohort of 412 male Scottish former international rugby union players and 1236 members of the general population, matched to former players by age, sex and area socioeconomic status. Mortality and incident neurodegenerative disease diagnoses among former rugby players were then compared with the matched comparison group.

Results Over a median 32 years follow-up from study entry at age 30 years, 121 (29.4%) former rugby players and 381 (30.8%) of the matched comparison group died. All-cause mortality was lower among former rugby players until 70 years of age with no difference thereafter. During follow-up, 47 (11.4%) former rugby players and 67 (5.4%) of the comparison group were diagnosed with incident neurodegenerative disease (HR 2.67, 95% CI 1.67 to 4.27, p<0.001).

Conclusions This study adds to our understanding of the association between contact sports participation and the risk of neurodegenerative disease. While further research exploring this interaction is required, in the meantime strategies to reduce exposure to head impacts and head injuries in sport should be promoted.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ High neurodegenerative disease mortality has been reported among former professional American footballers and soccer players. The risk of neurodegenerative disease among former rugby union players, however, remains unknown.

WHAT THIS STUDY ADDS

⇒ While overall, all-cause mortality was similar among Scottish male former international rugby players and their matched general population comparison group, mean age at death was slightly higher while risk of neurodegenerative disease was just over 2.5 times higher among former rugby players.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ These data provide further insight into the association between contact sports and neurodegenerative disease risk and add to evidence in support of the need for measures to reduce risk of head impacts and head injuries in sport, while also exploring strategies to mitigate risk of adverse brain health in former athletes.

INTRODUCTION

Traumatic brain injury (TBI) is recognised as a major risk factor for neurodegenerative disease and is estimated to be responsible for 3% of dementia in the general population.1 This association has attracted particular attention in recent years through autopsy reports of a neuropathology uniquely associated with a prior history of TBI or repetitive head impact exposure, chronic traumatic encephalopathy-neuropathologic change (CTE-NC), in former athletes from a range of sports, including American football,2 soccer (association football)3–5 and rugby union.6–9 To date, however, although CTE-NC has been documented in numerous studies of former athletes and others exposed to TBI and repetitive head impacts, there is only limited understanding of the risk of neurodegenerative disease among these populations.

Studies have reported higher neurodegenerative disease mortality among former National Football League (NFL) professional American football players9–9 and former professional soccer players.10–13 For example, among former professional soccer players overall neurodegenerative disease mortality is approximately 3.5-fold higher than among a general population comparison group matched by age and area socioeconomic status, with the risk ranging from a doubling of deaths with Parkinson’s disease to a fivefold increase in deaths with Alzheimer’s disease.14 Furthermore, evidence from professional soccer and American football suggests the risk of neurodegenerative disease reflects cumulative exposure to factors within the sport, with the risk of neurodegenerative disease higher with longer career lengths5,13 and in player positions associated with greater exposure to head impacts.15 Nevertheless, although thorough, these few studies report neurodegenerative disease
outcomes in exclusively professional athletes and from limited sports.

Played in over 120 countries internationally, with just under 10 million active participants, rugby union (hereafter ‘rugby’) is acknowledged as a contact sport in which there is a relatively high risk of concussion/mild TBI, with current data suggesting injury rates ranging 2.08 concussions/1000 player hours at community level to 19.8 concussions/1000 player hours in professional rugby. Although first played in the 19th century, rugby remained an amateur sport until 1995 when professionalism was permitted, and professional league competitions were instituted. To date, multiple autopsy-alism was permitted, and professional league competitions were instituted. To date, multiple autopsy-alism was permitted, and professional league competitions were instituted. To date, multiple autopsy-alism was permitted, and professional league competitions were instituted. To date, multiple autopsy-alism was permitted, and professional league competitions were instituted. To date, multiple autopsy-alism was permitted, and professional league competitions were instituted. To date, multiple autopsy-alism was permitted, and professional league competitions were instituted. To date, multiple autopsy-alism was permitted, and professional league competitions were instituted. To date, multiple autopsy-alism was permitted, and professional league competitions were instituted. To date, multiple autopsy-alism was permitted, and professional league competitions were instituted. To date, multiple autopsy-alism was permitted, and professional league competitions were instituted. To date, multiple autop

METHODS

Ethical approval was provided by the University of Glasgow College of Medical, Veterinary and Life Sciences Ethics Committee (Project Number 200200034), with protocol and data governance procedures reviewed and approved by National Health Service (NHS) Scotland’s Public Benefit and Privacy Panel for Health and Social Care (reference 1920–0262). As all data from health records were anonymised to researchers, participant-level consent was not required. The analysis and reporting of this study are consistent with the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines.

Cohort identification and inclusion criteria

Former international rugby players were identified from the book ‘Scottish Rugby: Game by Game’ by Kenneth Bogle, which lists all Scottish men’s international representative team players since 1890. This was cross-referenced and supplemented with publicly available information on Scottish international rugby players available via the website ESPNscrum.com. Available data included full name and date of birth of players and their field position. Study inclusion was restricted to individuals aged 30 years or over at 31 December 2020. Individuals with missing or incomplete date of birth were excluded. All subjects included in this study were male.

Matched population comparison group

Probabilistic matching was applied to the full name and date of birth of former rugby players to link them to their unique Community Health Index (CHI) number. Using this process, multiple demographic variables (such as date of birth or full name) were compared between the two datasets and a score reflecting the level of agreement allocated to each. The scores were then summed to provide the overall likelihood that

Lifelong health outcomes

Outcomes for all former rugby players and the matched population comparison group, whether living or deceased at the time of data capture, were obtained by individual-level record linkage to: hospitalisations, ascertained from Scottish Morbidity Record (SMR) 01 (General/Acute Inpatient and Day Case) and SMR04 (Mental Health Inpatient and Day Case) datasets; dispensed prescriptions ascertained from the national Prescribing Information System; and death certificates. SMR01, SMR04 and death certification datasets were accessed for each individual by matching to their unique CHI number, with all outcomes coded using the International Classification of DiseasesICD9/10. Online supplemental table 1 lists the ICD9/10 codes used to define the outcomes: neurodegenerative disease (all neurodegenerative diseases; dementia, not otherwise specified, Alzheimer’s disease, non-Alzheimer’s dementias, motor neuron disease (MND)/amyotrophic lateral sclerosis (ALS) and Parkinson’s disease), in addition to the remaining most common causes of death among adult Scottish males (diseases of the circulatory system (classified as all diseases of the circulatory system, ischaemic heart disease, and stroke or cerebrovascular disease), diseases of the respiratory system, or cancer (classified as any cancer or lung cancer)). The Prescribing Information System records every prescription dispensed in the community, with medications coded using the British National Formulary (BNF). The medications relevant to this study were coded under section 4.9 (drugs used in parkinsonism and related disorders, including drugs used in MND/ALS) and section 4.11 (drugs for dementia) of the BNF (online supplemental table 2). For all former players and the matched comparison group, neurodegenerative disease events were ascertained from the earliest coding of neurodegenerative disease captured from either hospitalisation or death certification (listed as the primary or contributing cause of death) or relevant medication captured from the prescribing database. SMR01, SMR04 and death certification data were available from 1 January 1981 and prescribing data were available from 1 January 2009. All analyses included data up to 31 December 2020, with database interrogation performed on 30 November 2021.

Statistical analyses

Cox proportional hazards models were used to model time to death and time to incident neurodegenerative disease, with results reported as hazard ratios (HRs) and 95% confidence intervals (95% CIs). Schoenfeld residuals were used to test the assumption of proportional hazards. Where the proportional hazards assumption did not hold, a time-varying model was used.

The SIMD is categorised into general population quintiles ranging from 1 (most deprived) to 5 (most affluent).
Neurodegeneration

to derive HR over different periods of follow-up. In the analysis of MND/ALS, zero events were recorded among the general population comparison group. To accommodate this, one general population observation was re-allocated from no event to event, with results reported as a Baptista-Pike mid-p odds ratio (OR) and 95% CI. All statistical analyses were undertaken using Stata v16, with statistical significance set at two-sided p<0.05.

RESULTS

Study cohort

A total of 654 former Scottish international rugby players were identified from available records. Of these, 414 were successfully matched to their CHI. The remaining 240 rugby players could not be matched to their CHI due to incomplete or inaccurate demographic information. Following CHI matching, a further two former rugby players were excluded because their last known postcode of residence could not be ascertained, precluding identification of appropriately matched general population individuals for comparison. The final cohort for analysis, therefore, comprised 412 former international rugby players and a comparison group of 1236 sex, age and area socio-economic status matched members of the general population (table 1) (online supplemental figure 1).

All-cause and neurodegenerative disease mortality among former international rugby players

Over a median of 32 years follow-up from study entry at the age of 30 years, 121 (29.4%) of 412 former rugby players and 381 (30.8%) of 1236 individuals in the general population comparison group died, with age at death higher among former rugby players than the comparison group (mean (±SD) 78.9±10.2 years vs 76.4±11.4 years; p=0.03) (figure 1). Overall, there was no difference in all-cause mortality between former international rugby players and the matched comparison group using a Cox proportional hazard model (HR 0.86, 95% CI 0.68 to 1.08, p=0.19) (table 2). However, the proportional hazards assumption was not met. All-cause mortality among former international rugby players was lower to age 70 years; thereafter, it was no different from that of the matched population comparison group (figure 2). All other analyses fulfilled the proportional hazards assumption.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Cohort demographic information</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Former international rugby players (n=412)</td>
</tr>
<tr>
<td>Number (%)</td>
<td></td>
</tr>
<tr>
<td>SIMD quintile</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>11 (2.7)</td>
</tr>
<tr>
<td>2</td>
<td>41 (10.0)</td>
</tr>
<tr>
<td>3</td>
<td>66 (16.0)</td>
</tr>
<tr>
<td>4</td>
<td>127 (30.8)</td>
</tr>
<tr>
<td>5</td>
<td>167 (40.5)</td>
</tr>
<tr>
<td>Player position</td>
<td></td>
</tr>
<tr>
<td>Forward</td>
<td>222 (53.9)</td>
</tr>
<tr>
<td>Front row</td>
<td>96 (23.3)</td>
</tr>
<tr>
<td>Lock</td>
<td>40 (9.7)</td>
</tr>
<tr>
<td>Back row</td>
<td>86 (20.9)</td>
</tr>
<tr>
<td>Backs</td>
<td>190 (46.1)</td>
</tr>
<tr>
<td>Half backs</td>
<td>58 (14.1)</td>
</tr>
<tr>
<td>Three quarters</td>
<td>111 (26.9)</td>
</tr>
<tr>
<td>Fullback</td>
<td>21 (5.1)</td>
</tr>
<tr>
<td>Year of birth</td>
<td></td>
</tr>
<tr>
<td>1900–1919</td>
<td>47 (11.5)</td>
</tr>
<tr>
<td>1920–1939</td>
<td>91 (22.1)</td>
</tr>
<tr>
<td>1940–1959</td>
<td>89 (21.6)</td>
</tr>
<tr>
<td>1960–1979</td>
<td>109 (26.4)</td>
</tr>
<tr>
<td>1980–1990</td>
<td>76 (18.5)</td>
</tr>
</tbody>
</table>

N/A, not applicable; SIMD, Scottish Index of Multiple Deprivation.

Figure 1 Mean (±SD) age at death for common causes of death among former international rugby players compared with a matched population comparison group. Overall age at death was higher in former international rugby players than a matched population comparison group (78.9±10.2 years vs 76.4±11.4 years, respectively; p=0.003). There was no difference in age at death for all mortality subtypes assessed.
assumption. No differences in mortality or age at death were observed between former rugby players and the general population comparison group for the most common primary causes of death for Scottish adult males, including cardiovascular disease, respiratory disease, cancer, and neurodegenerative disease (table 2, figure 1). However, when the analyses were repeated including both primary and secondary causes of death, risk of death with respiratory disease was lower (HR 0.61, 95% CI 0.37 to 0.99, p=0.045), while risk of death with neurodegenerative disease was higher (HR 2.60, 95% CI 1.44 to 4.70, p=0.002) among former rugby players than the comparison group. No differences in mortality were observed for the remaining causes of death using the composite outcome of primary and contributory cause of death.

**Neurodegenerative disease risk among former international rugby players**

Over the period of follow-up, 47 (11.4%) former international rugby players and 67 (5.4%) of the matched, general population comparison group had an incident neurodegenerative disease diagnosis, based on death certification, hospital admission or prescribing information (HR 2.67, 96% CI 1.67 to 4.27, p<0.001) (table 3). In addition to higher deaths with neurodegenerative disease, hospitalisation for neurodegenerative disease (HR 2.29, 95% CI 1.19 to 4.41, p=0.013) and prescriptions for medications used in neurodegenerative disease (HR 4.59, 95% CI 2.14 to 9.82, p<0.001) were higher among former rugby players than the comparison group. Furthermore, risk of incident neurodegenerative disease diagnosis varied by disease subtype (table 4).

**Player position and risk of neurodegenerative disease**

In a sub-group analysis of risk of incident neurodegenerative disease among former international rugby players, there was no difference in risk between forwards and backs (HR 1.00, 95% CI 0.56 to 1.78, p=0.991) (table 5).

**DISCUSSION**

Our findings demonstrate that, up to 70 years of age, all-cause mortality was lower among male, former Scottish international rugby union players than the general population. However, neurodegenerative disease was more likely to cause or contribute to deaths among former rugby players than the general population, in contrast to respiratory disease mortality which was less among former rugby players. This finding of higher neurodegenerative disease mortality was corroborated by a higher risk of incident neurodegenerative disease among rugby players. Finally, while risk of incident neurodegenerative disease varied by subtype among former rugby players, no difference in risk was observed between player positions when sub-grouped as either forwards or backs.

Our observation of an age-dependent relationship between former rugby players and all-cause mortality is consistent with our previous finding of a similar relationship among former soccer players.14 However, in contrast to former professional soccer players, we did not observe a reduced risk of deaths due to cardiovascular disease or cancer among former international rugby players, suggesting the possibility of sport-specific influences on lifelong health outcomes. In this context, between-sport differences in all-cause and cause-specific mortality have been reported elsewhere.8 There is, therefore, a continued need to consider broad, lifelong health outcomes among such players.

**Table 2** Primary cause of death among former international rugby players and a matched population comparison group

<table>
<thead>
<tr>
<th>Primary cause of death</th>
<th>Former international rugby players (n=412)</th>
<th>Matched population comparison group (n=1236)</th>
<th>HR (95% CI)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any cause†</td>
<td>121 (29.4%)</td>
<td>381 (30.8%)</td>
<td>0.86 (0.68 to 1.08)</td>
<td>0.19</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>54 (13.1%)</td>
<td>155 (12.5%)</td>
<td>0.89 (0.63 to 1.28)</td>
<td>0.534</td>
</tr>
<tr>
<td>Cancer</td>
<td>30 (7.3%)</td>
<td>108 (8.7%)</td>
<td>0.77 (0.50 to 1.19)</td>
<td>0.242</td>
</tr>
<tr>
<td>Neurodegenerative disease</td>
<td>11 (2.7%)</td>
<td>18 (1.5%)</td>
<td>2.43 (0.92 to 6.42)</td>
<td>0.073</td>
</tr>
<tr>
<td>Respiratory disease</td>
<td>11 (2.7%)</td>
<td>43 (3.5%)</td>
<td>0.62 (0.28 to 1.39)</td>
<td>0.247</td>
</tr>
</tbody>
</table>

*Cox proportional hazards regression.

†All-cause mortality analysis did not fulfill the proportional hazards assumption and showed time-dependent variability.

**Table 3** Neurodegenerative disease outcomes among former international rugby players compared with that of a matched population comparison group

<table>
<thead>
<tr>
<th></th>
<th>Former international rugby players (n=412)</th>
<th>Matched population comparison group (n=1236)</th>
<th>HR (95% CI)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>All NDD</td>
<td>47 (11.4%)</td>
<td>67 (5.4%)</td>
<td>2.67 (1.67 to 4.27)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Deaths</td>
<td>32 (7.8%)</td>
<td>39 (3.2%)</td>
<td>2.60 (1.44 to 4.70)</td>
<td>0.002</td>
</tr>
<tr>
<td>Hospitalisation</td>
<td>21 (5.1%)</td>
<td>37 (3.0%)</td>
<td>2.29 (1.19 to 4.41)</td>
<td>0.013</td>
</tr>
<tr>
<td>Prescribing NDD</td>
<td>24 (5.8%)</td>
<td>28 (2.3%)</td>
<td>4.59 (2.14 to 9.82)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*Cox proportional hazards regression.

NDD, neurodegenerative diseases.
The mortality outcomes observed in this retrospective cohort study of former international rugby players might appear at odds with data from a previous cross-sectional study of former international rugby players that reported a lower prevalence of cardiovascular disease than in a comparison group of similar age. Further, that study and other, similar cross-sectional studies in former rugby players demonstrated only limited evidence of minor, sub-clinical reductions in cognitive performance among former players. The differences are likely to reflect the methodological limitations of cross-sectional studies, such as being prone to survival bias. Since our study demonstrated higher mortality from neurodegenerative disease among former rugby players, former players with neurodegenerative disease are likely to be under-represented in a cross-sectional study. Previous cross-sectional studies may also have been subject to volunteer, or self-selection, bias which was obviated in our retrospective cohort study using secondary data.

The finding that former international rugby players have higher mortality with neurodegenerative disease than their matched, general population comparison group is consistent with similar observations from studies of former NFL7–9 and professional soccer players.10–13 Notably, in contrast to data from the NFL and soccer, our cohort of rugby players largely comprises amateur athletes, although participating at an elite, international level. In this respect, it is the first demonstration that high neurodegenerative disease risk is not a phenomenon exclusive to professional athletes. This is in line with data from autopsy studies on former athletes with dementia, where CTE pathology or dementia pugilistica, nor are we aware of a surrogate code which is used consistently and widely in clinical practice to capture putative diagnoses. As such, we have no information on this diagnosis. Nevertheless, the mixed neurodegenerative disease diagnoses captured in this study would be in line with similar observations in previous studies of former athletes,7,14 and with autopsy findings reporting mixed neurodegenerative pathologies among former rugby players with dementia. Further, while neurodegenerative disease risk overall was higher among former rugby players than the comparison group, our data suggest risk varied by neurodegenerative disease subtype, similar to observations in former NFL7 and professional soccer players.15

Perhaps most notable in this regard, while the absolute number of former rugby players diagnosed with MND was low in the present study, the high risk of MND observed relative to the matched, general population comparison group is at least consistent with, if not higher than, that observed in previous athlete studies.7,9,13 Furthermore, as we had to allocate an MND event to the comparison group, to obviate the problem of a zero count, the reported effect size is likely to be an underestimate of the true strength of association. Limited data suggest exposure to TBI, including sports concussion, might serve as a risk factor for MND.33–36 However, the risk observed in this study and similar athlete studies appears several-fold higher than that reported from research looking at non-sport associated TBI.36 As such, the possibility that head impacts and/or TBI in sport lead to greater risk of MND than non-sports TBI, or that an additional, unknown risk factor contributes to the remarkably high risk observed among these populations, might be considered. Certainly, there is an immediate need for further, robust studies considering the specific association between sport, traumatic brain injury and risk of this rare, but uniformly fatal, outcome.

Concussion risk in rugby union is recognised to be among the highest for contact sports,37 38 with data demonstrating increasing concussion incidence at the professional level.39 Around half of concussions occur during the tackle, with the majority of those experienced by the player making the tackle.40 In an effort to address concerns over concussion in the sport, rugby authorities have introduced initiatives directed towards improved injury detection41 and risk reduction in match play. Head impact exposures and concussion risk are not isolated to match play. As such, measures to reduce exposures in training might also be considered a priority.45 In addition to these primary prevention measures, interventions targeted towards risk mitigation among former rugby players with already accumulated head impact exposures might also be considered, including the development of specialist brain health clinics.44

A strength of our study is the inclusion of a relatively large number of former rugby players and, importantly, a matched general population comparison group, with outcomes derived from comprehensive electronic health records. As such, potential biases were minimised. However, we must recognise that 37% of our potential cohort of former international rugby players could not be matched to their health records. We cannot, therefore, exclude the possibility that there may be differences in outcomes between our matched and unmatched populations, although inaccurate and incomplete recording of names and dates of birth is likely to introduce random error, rather than bias. Further, as SMR datasets are used extensively to inform Scottish healthcare policy planning and in research, their quality is maintained through a set of validation rules.

Table 4 Neurodegenerative disease subtypes among former international rugby players compared with a matched population comparison group

<table>
<thead>
<tr>
<th>Neurodegenerative disease</th>
<th>HR/OR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dementia (NOS)</td>
<td>2.17 (1.26 to 3.72)</td>
<td>0.005*</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>3.04 (1.51 to 6.10)</td>
<td>0.002*</td>
</tr>
<tr>
<td>MND/ALS†</td>
<td>15.17 (2.10 to 178.96)</td>
<td>0.009†</td>
</tr>
</tbody>
</table>

* Cox proportional hazards regression.
†Baptista-Pike mid-p odds ratio.
HMND/ALS adjusted to accommodate zero events by transferring one general population observation from no event to event.
ALS, amyotrophic lateral sclerosis; MND, motor neuron disease; NOS, not otherwise specified.

Table 5 Player position and risk of neurodegenerative disease among former international rugby players compared with matched population controls

<table>
<thead>
<tr>
<th></th>
<th>Forwards (n=222)</th>
<th>Backs (n=190)</th>
<th>HR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All NDD</td>
<td>26 (11.7%)</td>
<td>21 (11.1%)</td>
<td>1.00 (0.56 to 1.78)</td>
<td>0.991</td>
</tr>
</tbody>
</table>

NDD, neurodegenerative diseases.
Nevertheless, previous work has shown a propensity to under-reporting of neurodegenerative disease case numbers when these and other such existing datasets are interrogated. Again, however, we have no reason to believe any error would systematically favour one study population over the other. Our observations included only adult male athletes who, although playing largely in an amateur era, nevertheless were participating at an elite level. As such, the applicability of our findings to youth, female and non-elite athletes remains uncertain. Finally, we have no information in the available datasets regarding total career length in rugby or history of head impact and traumatic brain injury exposure or of exposure to wider dementia risk factors. Further studies specifically designed to explore these questions should be pursued.

In summary, our data demonstrate neurodegenerative disease risk is higher among Scottish male former international rugby union players than the general population after matching for sex, age and area socioeconomic status. These data add to our understanding of the association between contact sports and lifelong health outcomes, specifically risk of adverse brain health outcomes. There remains a need for further research exploring the relationship between contact sports and risk of neurodegenerative disease. In the meantime, strategies to reduce exposure to head impacts and head injuries across all sports should continue to be developed and promoted, while measures to mitigate risk of adverse brain health in former athletes should be considered.

Twitter William Stewart @WllStewNeuro

Contributors ERR and DFM collated the former rugby player and matched population comparison group datasets and completed all the primary data analyses; ERR and WS provided a first draft of the manuscript and collated comments from all authors into a final submission draft; all authors contributed to discussions on data analysis and interpretation, revised the manuscript and approved the final version.

The corresponding author (WS) had full access to all the data in the study and had final responsibility for the decision to submit for publication and is responsible for the overall content as guarantor for the article.

Funding This work was supported by funding from: The Football Association and The Professional Footballers Association; National Institutes of Neurological Disorders and Stroke, US (U54NS115322; WS); and NHS Research Scotland (WS).

Disclaimer The funders of this work had no role in study design, data collection, analyses, interpretation, writing of the manuscript, or in the decision to submit the work for publication.

Competing interests The authors report no competing interests.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data available upon reasonable request and subject to appropriate approvals from National Health Service (NHS) Scotland’s Public Benefit and Privacy Panel for Health and Social Care.

Supplemental material This content has been supplied by the author(s).

It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not be commissioned or peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Donald Lyall http://orcid.org/0000-0003-3850-1487
William Stewart http://orcid.org/0000-0003-2199-2582

REFERENCES
Neurodegeneration

Neurodegenerative disease risk among former international rugby union players
Supplementary figures and tables

Supplementary Table 1: ICD-9 and ICD-10 codes for outcomes assessed.

<table>
<thead>
<tr>
<th>Disease</th>
<th>ICD-9</th>
<th>ICD-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurodegenerative disease</td>
<td>290.0 to .4; 294.1 &amp; .2;</td>
<td>F01 to F03; G12.2; G20; G21;</td>
</tr>
<tr>
<td></td>
<td>331.0 to .2 &amp; .6 to .9;</td>
<td>G23.1 to .3, .8 &amp; .9; G30;</td>
</tr>
<tr>
<td></td>
<td>332;</td>
<td>G31</td>
</tr>
<tr>
<td></td>
<td>335.2</td>
<td></td>
</tr>
<tr>
<td>Dementia, not otherwise specified</td>
<td>290.0 to .4; 294.1 &amp; .2;</td>
<td>F01 to F03; G23.1 to .3; G30;</td>
</tr>
<tr>
<td></td>
<td>331.0 to .2 &amp; .6 to .9;</td>
<td>G31</td>
</tr>
<tr>
<td>Motor neuron disease/Amyotrophic lateral</td>
<td>335.2</td>
<td>G12.2</td>
</tr>
<tr>
<td>sclerosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson's disease</td>
<td>332</td>
<td>G20; G21; G23.8 &amp; .9</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>390 to 459</td>
<td>I00 to I99</td>
</tr>
<tr>
<td>Respiratory disease</td>
<td>460 to 519</td>
<td>J00 to J99</td>
</tr>
<tr>
<td>Cancer</td>
<td>140 to 239</td>
<td>C00 to D49</td>
</tr>
</tbody>
</table>
Supplementary Table 2: British National Formulary (BNF) subsections and drugs assessed in the analysis of neurodegenerative disease related prescriptions.

<table>
<thead>
<tr>
<th>BNF section</th>
<th>Drugs</th>
</tr>
</thead>
</table>
| 4.9.1       | Apomorphine hydrochloride  
              | Apomorphine hydrochloride hemihydrate  
              | Carbidopa  
              | Co-beneldopa (Benserazide/levodopa)  
              | Co-careldopa (Carbidopa/levodopa)  
              | Entacapone  
              | Levodopa  
              | Levodopa/carbidopa/entacapone  
              | Opicapone  
              | Rasagiline mesylate  
              | Safinamide  
              | Selegiline hydrochloride  
              | Tolcapone |
| 4.9.2       | Orphenadrine hydrochloride  
              | Trihexyphenidyl hydrochloride |
| 4.9.3       | Riluzole |
| 4.11        | Donepezil hydrochloride  
              | Galantamine  
              | Idebenone  
              | Memantine hydrochloride  
              | Rivastigmine |
Supplementary Figure 1: Flow diagram of the creation of the final former international rugby player and matched general population comparison group.

654 international rugby player records submitted for CHI matching

240 failed CHI matching

414 former international rugby players CHI matched

2 former international rugby players removed as no final area postcode identified

General population comparison group matched on a 3:1 basis by sex, year of birth, and area socioeconomic status

Final cohort:
412 former international rugby players
Neurodegenerative disease risk among former international rugby union players
Supplementary figures and tables

<table>
<thead>
<tr>
<th>outcome assessed</th>
<th>ICD-9</th>
<th>ICD-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurodegenerative disease</td>
<td>290.0 to .4; 294.1 &amp; .2; 331.0 to .2 &amp; .6 to .9; 332; 335.2</td>
<td>F01 to F03; G12.2; G20; G21; G23.1 to .3, .8 &amp; .9; G30; G31</td>
</tr>
<tr>
<td>Dementia, not otherwise specified</td>
<td>290.0 to .4; 294.1 &amp; .2; 331.0 to .2 &amp; .6 to .9;</td>
<td>F01 to F03; G23.1 to .3; G30; G31</td>
</tr>
<tr>
<td>Motor neuron disease/Amyotrophic lateral sclerosis</td>
<td>335.2</td>
<td>G12.2</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>332</td>
<td>G20; G21; G23.8 &amp; .9</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>390 to 459</td>
<td>I00 to I99</td>
</tr>
<tr>
<td>Respiratory disease</td>
<td>460 to 519</td>
<td>J00 to J99</td>
</tr>
<tr>
<td>Cancer</td>
<td>140 to 239</td>
<td>C00 to D49</td>
</tr>
</tbody>
</table>
Supplementary Table 2: British National Formulary (BNF) subsections and drugs assessed in the analysis of neurodegenerative disease related prescriptions.

<table>
<thead>
<tr>
<th>BNF section</th>
<th>Drugs</th>
</tr>
</thead>
</table>
| 4.9.1       | Apomorphine hydrochloride  
              Apomorphine hydrochloride hemihydrate  
              Carbidopa  
              Co-beneldopa (Benserazide/levodopa)  
              Co-careldopa (Carbidopa/levodopa)  
              Entacapone  
              Levodopa  
              Levodopa/carbidopa/entacapone  
              Opicapone  
              Rasagiline mesylate  
              Safinamide  
              Selegiline hydrochloride  
              Tolcapone |
| 4.9.2       | Orphenadrine hydrochloride  
              Trihexyphenidyl hydrochloride |
| 4.9.3       | Riluzole |
| 4.11        | Donepezil hydrochloride  
              Galantamine  
              Idebenone  
              Memantine hydrochloride  
              Rivastigmine |
Supplementary Figure 1: Flow diagram of the creation of the final former international rugby player and matched general population comparison group.

654 international rugby player records submitted for CHI matching

240 failed CHI matching

414 former international rugby players CHI matched

2 former international rugby players removed as no final area postcode identified

General population comparison group matched on a 3:1 basis by sex, year of birth, and area socioeconomic status

Final cohort:
412 former international rugby players